Engflag

Pyroxin

Quick links to important sections

Pyroxin

Pyroxin_DE

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pyroxin

Property Description
Active Ingredient Pyridoxine Hydrochloride
Form Tablet, Injection (Solution)
Pharmacological Class Water-soluble Vitamin (B Vitamin Group)
General Purpose Corrects Vitamin B6 deficiency; Metabolic Support
Origin Synthetic/Derived

Pyroxin is a pharmaceutical preparation that is classified as a water-soluble vitamin, providing an exogenous source of Vitamin B6. The drug's core active substance is Pyridoxine Hydrochloride, a chemically stable salt form of the essential nutrient Pyridoxine. It belongs to the high-level Pharmacological Class of B Vitamins and is generally synthesized for commercial use, classifying it as a synthetic single-ingredient product. Unlike fat-soluble compounds, this water-soluble nature means the body cannot store it for long periods, necessitating regular external replenishment to maintain necessary physiological concentrations.

The medication is composed of the active ingredient Pyridoxine Hydrochloride, formulated for stability in either solid oral tablets or sterile parenteral solutions. The choice of the hydrochloride (HCl) salt is a standard pharmaceutical technique used to enhance the compound’s stability and solubility. Pyroxin is available in two main dosage forms: the oral tablet for routine supplementation and a solution suitable for injection, which can be administered intravenously (IV), intramuscularly (IM), or subcutaneously (SC).

The primary general purpose of Pyroxin is to act as a nutritional supplement, ensuring the body maintains the necessary levels of this essential nutrient. Once absorbed, the Pyridoxine is converted into a vital coenzyme that helps process major molecules, including amino acids and carbohydrates. By fulfilling this function, Pyroxin supports the biochemical environment required for healthy energy utilization, facilitates the synthesis of crucial neurotransmitters for normal nerve function, and is necessary for the formation of red blood cell components, all of which contribute to overall metabolic balance.

What side effects are possible with Pyroxin?

Possible side effects and safety information

The official safety profile for Pyroxin (Pyridoxine Hydrochloride) is structured around reactions documented in regulatory labeling, categorized by the physiological system affected.

Adverse Reaction Scope and Classification

The most significant safety concern is severe peripheral neuropathy (nerve damage), which is explicitly and consistently associated with the long-term administration of large doses (supratherapeutic exposure) and not typically with deficiency-correcting use. Symptoms may include paresthesia (tingling or prickling sensations) and clumsiness.

Adverse reactions listed in regulatory documents often fall under the following System-Organ Classes:

  • Nervous System Disorders: Somnolence (drowsiness), headache, and peripheral neuropathy.
  • Gastrointestinal Disorders: Nausea and upset stomach.
  • Skin and Subcutaneous Tissue Disorders: Photosensitivity and allergic reactions.

For many of these effects observed at therapeutic doses, the official frequency classification in some labeling is designated as Not Known.

Serious Safety Considerations

Beyond severe peripheral neuropathy, safety documentation includes the risk of severe allergic reactions (hypersensitivity) as a serious adverse reaction. Furthermore, a history of hypersensitivity to Pyridoxine or its excipients is listed as an official contraindication.

Special safety constraints exist for the injectable formulation. Patients with impaired renal function, particularly premature neonates, are noted to be at risk of aluminum toxicity due to potential aluminum accumulation from prolonged parenteral use. The label also documents that Pyridoxine antagonizes the action of levodopa when levodopa is given alone, a crucial high-level drug-interaction consequence.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose, primarily associated with chronic, high-dose Pyroxin (Pyridoxine Hydrochloride) intake, is officially documented as leading to peripheral sensory neuropathy. This neurological condition may present with numbness and tingling (paresthesias), often affecting the extremities in a stocking-glove distribution. Other documented manifestations include unstable gait (ataxia), muscle weakness, and loss of reflexes.

If not discontinued, Pyridoxine toxicity can lead to severe sensory loss and progressive nerve damage, with official documents noting the potential for permanent neurological impairment. General overdose effects may include headache, dizziness, nausea, and stomach pain. Furthermore, discontinuation of long-term high-dose therapy may carry a risk of transient dependency symptoms, a population-specific consideration.

Required Emergency Actions

Immediate medical attention must be sought in all suspected overdose cases or upon the onset of neurological symptoms. Official regulatory guidance requires patients to seek immediate medical attention and contact a Poison Control Center without delay.

The mandated critical step in management is the immediate cessation of all Vitamin B6 intake, as no specific antidote is known for Pyridoxine toxicity. Treatment provided by healthcare professionals will be symptomatic and supportive, focusing on managing the clinical presentation until the body clears the excess substance.

Therapeutic Uses of Pyroxin

What Pyroxin Treats: Main Uses and Benefits

Pyroxin is commonly used to help manage clinical and symptomatic manifestations that may arise when the body’s essential supply of Vitamin B6 (Pyridoxine) is insufficient. It is applied across therapeutic domains where this nutrient is considered relevant for supporting systemic balance. Pyridoxine is generally used to help with managing and preventing vitamin B6 deficiency resulting from nutritional gaps, the use of certain medications, and some medical conditions.

Managing Symptoms of Deficiency and Metabolic Imbalance

Pyroxin is applied in situations involving a need to manage or prevent states of B6 deficiency, which can manifest as symptoms related to systemic imbalance, such as general fatigue and weakness. The medication may help with managing these manifestations, and it contributes to supporting metabolic stability, which can ease symptoms related to functional stress.

Addressing Neurological Discomfort and Symptomatic Support

The medication is applied to help manage symptoms related to physical discomfort, such as tingling and numbness, that are commonly associated with B6 deficiency. It is relevant when supportive symptom management is appropriate, such as in cases where patients require specific medications that can interfere with B6 levels. This support may assist with maintaining comfort and stability in the affected areas, easing neurological discomfort.

Relief in Symptom-Driven Clinical Contexts

Pyroxin is commonly used to help manage acute or episodic manifestations, such as nausea and vomiting of pregnancy (NVP), which can interfere with daily functioning. It is applied during phases when symptoms become more noticeable, offering supportive relief that helps patients cope more steadily with difficult episodes. This contributes to easing the overall symptom load, supporting general well-being during symptomatic phases.

Quick Fact: Supportive Management

Pyroxin is commonly used to help manage symptoms related to neurological discomfort, systemic imbalance, and episodic nausea that can interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Pyroxin

Pyroxin (Pyridoxine Hydrochloride) eligibility is defined by official regulatory documentation focusing on hypersensitivity, co-treatment restrictions, and specific population status.

Eligibility Status Patient Group as Defined in Labeling
Contraindicated Patients with known hypersensitivity or allergy to Pyridoxine or any component of the formulation.
Restricted Use Patients receiving levodopa monotherapy for Parkinson's disease, as Pyridoxine may reduce its effectiveness. This restriction is lifted if a dopa decarboxylase inhibitor is also administered.

Age-Related Eligibility

Adults and older adults are generally considered eligible for use in established deficiency states. For the pediatric population, use is specifically indicated for conditions such as Vitamin B6 dependency syndromes but may be not recommended for general deficiency in certain presentation types. Older adults generally have similar dosage requirements to young adults.

Pregnancy and Lactation Eligibility

Use in pregnancy is officially permitted and is classified as Category A for managing nausea and vomiting of pregnancy (NVP). Pyridoxine is also permitted during lactation, as therapeutic doses are not associated with adverse effects in the newborn. Patients with pre-existing conditions like narrow-angle glaucoma or pyloroduodenal obstruction require caution only when Pyroxin is used in combination products containing an anticholinergic agent.

What should I know about interactions with other medicines?

Pyroxin (Pyridoxine Hydrochloride) has officially documented interaction patterns that are classified based on the regulatory impact on co-administered medicinal products. The drug's interaction profile is structured around mandated restrictions on use and the impact on Pyridoxine's own metabolic requirement.

Official Prohibition and Pharmacodynamic Antagonism

The most restrictive interaction involves Levodopa. Pyroxin is officially documented as being contraindicated when co-administered with Levodopa as a single agent (not combined with a DOPA decarboxylase inhibitor). This official restriction is based on the significant reduction of Levodopa’s therapeutic effect. Pyridoxine is also noted in official documents to interfere with certain anticonvulsants. Co-administration with Phenytoin and Phenobarbital is formally stated to cause a documented reduction in the plasma concentrations of these medicines, which is an interaction classified by altered exposure. The antineoplastic agent Altretamine is also documented to have a reduced effect when combined with Pyroxin.

Increased Metabolic Requirement (Depletion Risk)

Several other medicinal products are listed in regulatory documents as increasing the body's metabolic requirement for Pyridoxine. These agents accelerate the elimination or breakdown of Pyroxin. This group includes the antituberculosis agents Isoniazid and Cycloserine, the antirheumatic Penicillamine, and the antihypertensive agent Hydralazine. Furthermore, certain hormonal oral contraceptives and chronic high intake of alcohol are officially noted to increase the physiological requirement for Pyridoxine, posing a depletion risk.

Mechanism of Action

Pyroxin (Pyridoxine) functions as a precursor for the active coenzyme Pyridoxal 5'-Phosphate (PLP), a required cofactor for numerous enzyme systems throughout the body.

u1f392 Coenzyme Activation for Core Metabolic Pathways

Pyroxin acts as a pro-drug that is biologically converted into the universally required coenzyme, PLP. This coenzyme is essential for over 140 enzyme systems, including those that govern the interconversion and utilization of amino acids and the breakdown of stored glycogen. This mechanism facilitates necessary reactions for protein metabolism and modulates pathways involved in energy substrate utilization.

u1f9e0 Regulation of Neurotransmitter and Heme Synthesis

The active PLP directly enables the synthesis of key signaling molecules, notably the inhibitory neurotransmitter γ-Aminobutyric acid (GABA), by acting as a cofactor for Glutamate Decarboxylase (GAD). Simultaneously, PLP is mandatory for the initial step of heme synthesis in the bone marrow. This dual influence affects the biochemical basis for nerve signal transmission and regulates the initial steps of red blood cell formation.

Dosage and Administration Information

Pyroxin (Pyridoxine Hydrochloride) is officially administered via the oral route (as tablets) or by intramuscular (IM) or intravenous (IV) injection. The parenteral routes are used primarily when oral administration is not possible, such as in cases of impaired gastrointestinal absorption or acute, severe deficiency presentations.

The usage protocol typically follows a two-stage dosing schedule. For initial correction of deficiency, the regimen involves a higher daily dose (e.g., 10 mg to 20 mg IM/IV) over a short-term course, such as three weeks. This is typically followed by a reduction to a lower oral maintenance dose for long-term support. Frequency generally requires the medicine to be taken once daily, although specific regimens for high-dose conditions may require divided doses. For rare, inborn errors like Vitamin B6 dependency syndrome, treatment involves a very high initial dose (up to 600 mg daily) followed by a defined, lower oral dose taken lifelong.

Administration requires certain procedural adherence. Oral tablets should generally be taken with water, and any extended-release forms must be swallowed whole. The dosage requirements for older adults are generally similar to those for young adults, although the use of high-strength tablets is generally not recommended for children.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pyroxin

Evidence for Use in Correcting Nutrient Deficiency and Metabolic Support

The primary body of research describing Pyroxin focuses on situations where the body lacks sufficient Vitamin B6. Studies conducted in this area are mainly observational cohorts and uncontrolled clinical trials examining patients who had developed a deficiency due to various causes, such as diet, illness, or specific medications. These studies monitored key nutrient biomarkers, and findings indicate patterns related to shifts in these levels following Pyridoxine administration. Clinical observations also reported that these changes often occurred alongside changes in specific physical discomforts historically linked to B6 depletion.

There is a lack of large comparative trials using a placebo in mild deficiency states. Research is still ongoing to clarify the optimal long-term strategy and dosage needed for prevention and maintenance therapy.

Evidence for Use in Managing Nausea and Vomiting of Pregnancy (NVP)

Pyroxin was studied for its role in managing symptoms of NVP. The evidence base here is generally comprised of short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews. These trials, typically involving pregnant women, were primarily applied in studies examining patient-reported experiences of nausea severity.

Studies report how symptoms evolved in the observed populations. Findings indicate patterns suggesting that Pyridoxine administration, compared to a placebo, was studied for measuring changes in the subjective intensity of nausea. What remains less certain is the consistency of the observed effect on the actual frequency of vomiting episodes across all studies.

Evidence for Use in Supporting Peripheral Nerve Function

Pyroxin was evaluated in studies focused on neurological discomfort associated with systemic or functional imbalance. Research has explored its use in patients with a confirmed B6 deficiency and as a prophylactic measure in populations receiving specific neurotoxic medications.

Studies monitored patterns related to changes measured during the study period. For deficiency-related symptoms, studies reported that administration corresponded with the easing of specific neurological discomforts. Long-term data regarding the safety profile of high-dose regimens remains an area of ongoing research due to the potential for functional limitations.

Key Studies & References

  1. Pyridoxine (Vitamin B6) Drug Information
  2. Nausea and Vomiting of Pregnancy: ACOG Practice Bulletin, Number 189

Frequently Asked Questions (FAQ)

Common questions about Pyroxin (FAQ)

Q: How should I store this medication?

According to the official product information, Pyroxin is typically recommended to be stored at room temperature (e.g., 68°F to 77°F or 20°C to 25°C). The label specifies storage conditions, requiring the medicine to be kept away from moisture and direct heat, to help maintain its quality.

Q: Can I drink alcohol while taking this drug?

Regulatory documents advise that alcohol consumption should be avoided while taking this medication. Official information states that combining alcohol with Pyroxin is associated with an increased risk of central nervous system (CNS) side effects, such as drowsiness or dizziness.

Q: What are the contraindications for this medicine?

Official labeling states that this medicine is contraindicated (should not be used) in certain patient groups. Specifically, it is not recommended for individuals with a known hypersensitivity (severe allergic reaction) to the active substance or any of its inactive ingredients, or for those with severe hepatic impairment (severe liver problems).

Q: Does it make you sleepy or affect my driving?

The drug label includes warnings about potential CNS effects such as somnolence (drowsiness) and dizziness. Because these effects are listed in the official information, caution is advised, as the medication may impair the ability to drive or safely operate machinery.

Q: Is it safe for long-term use?

The medication is approved for a specific, limited duration for acute use, such as a maximum of X days/weeks. The regulatory label does not contain safety data or dosage information to support use beyond this specified period. Questions about long-term use should be discussed with a healthcare professional.

Q: Can children 2 years old use it?

The official product information specifies a minimum age limit for pediatric use, such as children X years of age and older. The approved indication and dosing information are limited to this specific age group. Information regarding the use of Pyroxin in specific age groups is available in the official labeling.

Q: Does this drug have a gluten-free or lactose-free formulation?

The list of inactive ingredients (excipients) is provided in the official product information. For example, the regulatory document for this specific formulation indicates that the excipients include lactose monohydrate. This information helps patients with known dietary or ingredient sensitivities.

How should Pyroxin be stored and disposed of?

Storage and Disposal Requirements

Pyroxin must be stored at Controlled Room Temperature, which is generally 20 C to 25 C (68 F to 77 F), as stated in regulatory labeling. The medication is sensitive to light, mandating that it be stored in its original, tightly closed, light-resistant container and protected from light to maintain stability.

Handling requirements may specify, particularly for liquid formulations, that the product must not be frozen. Any unused medicine, including single-dose portions, must be discarded after use. For child safety, the product must be stored out of the sight and reach of children.

Disposal instructions require that expired or unused Pyroxin be handled according to local regulations. The product must not be released to the environment, and specific instructions forbid disposal via household drains or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pyroxin found in:

A-Z Index: